High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients
- 1 May 2020
- journal article
- letter
- Published by Elsevier in Journal of Hepatology
- Vol. 72 (5) , 1028-1029
Abstract
No abstract availableKeywords
Funding Information
- Unitaid
This publication has 8 references indexed in Scilit:
- Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trialJournal of Hepatology, 2020
- The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimensBMC Infectious Diseases, 2019
- The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analysesScientific Reports, 2019
- Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatmentBMC Infectious Diseases, 2018
- The epidemiology of hepatitis C virus in Pakistan: systematic review and meta-analysesRoyal Society Open Science, 2018
- Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic reviewThe Lancet Global Health, 2017
- Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injuryBMC Infectious Diseases, 2016
- The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in EgyptThe Lancet, 2000